NeurAxis to Participate in Lytham Partners Fall Investor Conference
CARMEL, Ind. — NeurAxis, Inc. (NYSE American: NRXS), a leading medical technology company, is preparing to highlight its advancements in neuromodulation therapies at the upcoming Lytham Partners Fall 2024 Investor Conference. This important event, which focuses on innovations designed to tackle chronic conditions, will be held virtually on a date to be announced in early autumn.
Engaging Webcast Presentation
The centerpiece of the conference will be a webcast presentation from NeurAxis, set for 12:30 p.m. ET. Attendees are invited to tune in to learn about the company's groundbreaking solutions and its future plans in the field of neuromodulation. The webcast will be accessible online, allowing participants to join from anywhere.
Chance for One-on-One Meetings
Alongside the presentation, NeurAxis management will hold virtual one-on-one meetings throughout the event. Investors eager to discuss the company's vision and strategies directly are encouraged to schedule these meetings. This interaction offers a valuable opportunity to explore NeurAxis's operations and aspirations in greater detail.
About NeurAxis and Its Cutting-Edge Therapies
NeurAxis is committed to creating neuromodulation therapies aimed at treating debilitating conditions affecting both children and adults. Their flagship IB-Stim™ therapy utilizes state-of-the-art Percutaneous Electrical Nerve Field Stimulation technology, which has received FDA clearance specifically for alleviating functional abdominal pain related to irritable bowel syndrome (IBS) in adolescents aged 11 to 18. As part of its dedication to improving healthcare, NeurAxis is actively pursuing further clinical trials to investigate the uses of PENFS across various pediatric and adult conditions.
Company’s Dedication to Advancements in Medicine
NeurAxis’s main mission is to enhance patient care through scientific innovation and evidence-based practices. The organization is resolute in its efforts to improve the quality of life for individuals living with chronic conditions. By concentrating on innovative treatment options, NeurAxis aims not just to tackle current challenges but also to pave the way for future advancements in medical technology.
Contact Information for Further Inquiries
If you’re looking for more information about NeurAxis or wish to make inquiries regarding investor relations, please reach out to:
Company:
NeurAxis, Inc.
Email: info@neuraxis.com
Investor Relations:
Lytham Partners
Ben Shamsian
646-829-9701
Email: shamsian@lythampartners.com
Frequently Asked Questions
What is NeurAxis known for?
NeurAxis is recognized for its innovative neuromodulation therapies aimed at treating chronic conditions in children and adults.
What can we expect from NeurAxis at the conference?
NeurAxis will present its advancements in neuromodulation therapies, particularly its IB-Stim™ technology used for relieving abdominal pain associated with IBS.
When will the webcast presentation take place?
The webcast is scheduled for 12:30 p.m. ET on the day of the event and will be streamed online for all attendees to view.
Are there opportunities for investors to meet with NeurAxis management?
Yes, investors can set up virtual one-on-one meetings with NeurAxis management throughout the conference.
How can I get in touch with NeurAxis for more information?
You can contact NeurAxis by emailing info@neuraxis.com for general inquiries, or reach out to Lytham Partners for investor relations at shamsian@lythampartners.com.
